Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Fontanellas-Romá, A. (Antonio) | - |
dc.creator | Avila, M.A. (Matías Antonio) | - |
dc.creator | Anderson, K.E. (Karl E.) | - |
dc.creator | Deybach, J.C. (Jean-Charles) | - |
dc.date.accessioned | 2024-01-31T10:56:06Z | - |
dc.date.available | 2024-01-31T10:56:06Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Fontanellas-Romá, A. (Antonio); Avila, M.A. (Matías Antonio); Anderson, K.E. (Karl E.); et al. "Current and innovative emerging therapies for porphyrias with hepatic involvement". Journal of Hepatology. 71 (2), 2019, 422 - 433 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10171/68668 | - |
dc.description.abstract | Porphyrias are rare inherited disorders caused by specific enzyme dysfunctions in the haem synthesis pathway, which result in abnormal accumulation of specific pathway intermediates. The symptoms depend upon the chemical characteristics of these substances. Porphyrins are photoreactive and cause photocutaneous lesions on sunlight-exposed areas, whereas accumulation of porphyrin precursors is related to acute neurovisceral attacks. Current therapies are suboptimal and mostly address symptoms rather than underlying disease mechanisms. Advances in the understanding of the molecular bases and pathogenesis of porphyrias have paved the way for the development of new therapeutic strategies. In this Clinical Trial Watch we summarise the basic principles of these emerging approaches and what is currently known about their application to porphyrias of hepatic origin or with hepatic involvement. | es_ES |
dc.description.sponsorship | This study was supported in part by grants from the Spanish Fundación Eugenio Rodríguez Pascual and Spanish Institute of Health Carlos III (FIS) co-financed by European FEDER funds (grant numbers PI15/01951 and PI18/00860). | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Porphyrias | es_ES |
dc.subject | mRNA therapy | es_ES |
dc.subject | Heme synthesis | es_ES |
dc.subject | RNA interference technology | es_ES |
dc.subject | Liver gene therapy | es_ES |
dc.subject | Direct-acting antiviral agents and PCT | es_ES |
dc.subject | Hematopoietic-stem-cell-based gene therapy | es_ES |
dc.subject | Lentiviral vectors | es_ES |
dc.subject | Melanogenesis stimulator | es_ES |
dc.subject | Antisense oligonucleotide therapy | es_ES |
dc.title | Current and innovative emerging therapies for porphyrias with hepatic involvement | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S016882781930282X#:~:text=Acute%20hepatic%20porphyrias,-Acute%20hepatic%20porphyrias&text=Acute%20hepatic%20porphyrias%20are%20characterised,and%20gene%20or%20mRNA%20addition. | es_ES |
dc.editorial.note | © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. | es_ES |
dadun.citation.endingPage | 433 | es_ES |
dadun.citation.number | 2 | es_ES |
dadun.citation.publicationName | Journal of Hepatology | es_ES |
dadun.citation.startingPage | 422 | es_ES |
dadun.citation.volume | 71 | es_ES |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.